ReShape Lifesciences Inc. (RSLS)
Aug 15, 2025 - RSLS was delisted (reason: merged into HIND)
15.68
0.00 (0.00%)
Inactive · Last trade price on Aug 14, 2025

ReShape Lifesciences Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2020
Period Ending
Aug '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2020
113532920
Upgrade
Market Cap Growth
29.54%-31.25%42.48%-88.82%48.32%1073.04%
Upgrade
Enterprise Value
733-3328
Upgrade
Last Close Price
15.68446.001448.2639091.95475596.671029492.79
Upgrade
PS Ratio
0.200.400.530.292.131.73
Upgrade
PB Ratio
1.76-12.560.690.890.651.35
Upgrade
P/TBV Ratio
1.81-0.690.951.23-
Upgrade
EV/Sales Ratio
1.010.330.40-0.242.48
Upgrade
Debt / Equity Ratio
0.02-3.820.040.050.010.92
Upgrade
Asset Turnover
0.841.040.800.350.300.30
Upgrade
Inventory Turnover
0.830.950.851.342.002.83
Upgrade
Quick Ratio
1.530.341.620.813.400.48
Upgrade
Current Ratio
2.770.922.731.333.980.77
Upgrade
Return on Equity (ROE)
-101.49%-222.47%-220.59%-192.58%-214.70%-112.09%
Upgrade
Return on Assets (ROA)
-53.96%-53.93%-83.92%-53.16%-34.82%-20.30%
Upgrade
Return on Capital (ROIC)
-90.61%-109.11%-170.11%-69.87%-43.11%-27.20%
Upgrade
Earnings Yield
-42.60%-224.34%-246.32%-1424.32%-217.66%-110.58%
Upgrade
FCF Yield
-72.09%-139.29%-367.80%-679.06%-54.21%-45.70%
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q